Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 196

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 196
---
, 2024, we received a letter from the Listing Qualifications Department of Nasdaq stating that, pursuant to Nasdaq Listing Rule IM -5101-2, Nasdaq’s staff had determined that (i) our securities will be delisted from Nasdaq, (ii) trading of our SPAC Class A Ordinary Shares, Public Warrants, and SPAC Units would be suspended at the opening of business on December 17, 2024 and (iii) a Form 25 -NSEwill be filed with the SEC, which will remove our securities from listing and registration on Nasdaq. Under Rule IM -5101-2, a special purpose acquisition company must complete one or more business combinations within 36 months of the effectiveness of its initial public offering registration statement. Since we failed to complete our initial business combination by December 6, 2024, Nasdaq’s staff concluded that the we did not comply with Rule IM -5101-2and that our securities are now subject to delisting. As a result, trading in our securities on Nasdaq was effectively suspended with the open of the market on December 17, 2024, and our securities are currently eligible to trade only on the over -the -countermarkets system. On March21, 2025, Nasdaq filed a Form 25 -NSEin respect of APx’s Class A ordinary shares with the SEC, and the delisting of APx’s Class A ordinary shares became effective on March31, 2025. On May8, 2025, Nasdaq filed a Form 25 -NSEin respect of APx’s units and warrants with the SEC, and the delisting of APx’s units and warrants will become effective on May18, 2025. Following the delisting on Nasdaq, APx’s Class A ordinary shares are quoted on the Pink Open Market of the OTC under the symbol “APXIF”. We will remain a reporting entity under the Securities Exchange Act of 1934, as amended, with respect to continued disclosure of financial and operational information. Despite the delisting of our securities from Nasdaq, we intend to proceed with our efforts to consummate our initial Business Combination. However, Nasdaq approval of OmnigenicsAI’s initial listing application with respect to the Business Combination is a condition to such Business Combination, and there can be no guarantee that Nasdaq will approve such initial listing application, which may delay, or ultimately prevent the consummation of the proposed Business Combination. There can be